Relmada Therapeutics (Relmada Therapeutics) 6-Month Price Index : 1.09 (As of May. 24, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-05-24), Relmada Therapeutics's 6-Month Price Index is 1.09.

Competitive Comparison of Relmada Therapeutics's 6-Month Price Index

For the Biotechnology subindustry, Relmada Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relmada Therapeutics (NAS:RLMD) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics (NAS:RLMD) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Relmada Therapeutics 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics (Relmada Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

4E2:Germany

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Executives

Cedric O'gorman	officer: Chief Medical Officer	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli	director	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa	director, officer: Chief Executive Officer	138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly	director	300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel	officer: EVP, Head of R&D	15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence	officer: Chief Financial Officer	3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo	officer: Chief Medical Officer	71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar	director	P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas	officer: President and CSO	7707 GATEWAY BLVD, NEWARK CA 94560